A landmark achievement for SD Biosensor was the WHO prequalification of their STANDARD G6PD Test in December 2024. This recognition marked the first point-of-care test for G6PD deficiency to receive WHO prequalification, opening new avenues for safer malaria treatment globally. The achievement was particularly significant because G6PD deficiency affects approximately 400 million people worldwide, particularly in malaria-endemic regions.

STANDARD Q COVID-19 Ag Test

Trusted by Global Health. Built for Better Diagnostics.

SD BIOSENSOR’s journey in in-vitro diagnostics has been marked by significant global public-health milestones, reflecting its commitment to developing accessible, reliable and high-quality diagnostic solutions.

A landmark achievement came in September 2020, when the STANDARD Q COVID-19 Ag Test became the first rapid antigen diagnostic test to be listed under the World Health Organization’s Emergency Use Listing (EUL). This milestone enabled rapid deployment of the test across more than 100 countries during the COVID-19 pandemic, supporting the global need for accessible and timely testing.

The journey continued with WHO prequalification of the STANDARD Q COVID-19 Ag Test in December 2025, marking another important recognition of the product within the global WHO prequalification framework.

STANDARD Q Malaria P.f/P.v Ag Test and STANDARD Q Malaria P.f Ag Test

SD BIOSENSOR’s WHO-recognized portfolio extends beyond COVID-19 diagnostics. Its STANDARD Q Malaria P.f/P.v Ag Test and STANDARD Q Malaria P.f Ag Test achieved WHO prequalification in 2020, supporting malaria diagnosis in resource-limited and endemic settings.

STANDARD Q HCV Ab Test

The SD Biosensor STANDARD Q HCV Ab Test was also included in the WHO prequalified IVD portfolio in 2020

STANDARD G6PD Test

The STANDARD G6PD Test was added to the WHO list in December 2024. The G6PD system provides semi-quantitative measurement of G6PD activity from whole-blood samples.